Peripheral blood cells as prognostic markers in patients with advanced non-small cell lung cancer treated with cemiplimab as monotherapy or in combination with chemotherapy
Published in Cancer Treatment and Research Communications, 2025
Recommended citation: R. J. Acosta, D. A. G. McIntyre, J. C. Murray, V. Anagnostou, J. R. Brahmer, T. Sims, G. A. Daniels, A. Meisel, A. Sezer, M. Gogishvili, T. Melkadze, A. Baramidze, T. Makharadze, A. Y. He, V. Jankovic, G. Geba, A. Pillai, F. Seebach, P. Rietschel, G. Gullo, J. Pouliot, and Y. Kim. Peripheral blood cells as prognostic markers in patients with advanced non-small cell lung cancer treated with cemiplimab as monotherapy or in combination with chemotherapy. Cancer Treat. Res. Commun. doi:10.1016/j.ctarc.2025.100959.
Download Paper